Angiotech Pharmaceuticals — Merger or Acquisition (July 2008)
15 slides from Angiotech Pharmaceuticals's merger presentation, Jul 7, 2008
Slide 1: Schedule 14A Proxy Statement
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy
Slide 2: Filing Party / Date Filed
(3) Filing Party: (4) Date Filed:
Slide 3: Angiotech Pharmaceutical Interventions
Filed by Angiotech Pharmaceuticals, Inc. Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Angiotech Pharmaceuticals, Inc. Commission File No.: 000-30334 Angiotech Pharmaceutical Interventions July 7, 2008
Slide 4: Forward-Looking Statements
2 Forward-Looking Statements Statement contained in this presentation that are not based on historical fact, including without limitation statements containing the words “believes”, “may”, “plans”, “will”, “estimate”, “continue”, “anticipates”, “intends”, “expects” and similar expressions,constitute
Slide 5: Proxy Statement Legend Language
3 Proxy Statement Legend Language Additional Information and Where to Find It – This communication may be deemed to be solicitation material in respect of the proposed investment of Ares Corporate Opportunities Fund III, L.P., New Leaf Ventures I, L.P. and New Leaf Ventures II, L.P. in Angiotech’s s
Slide 6: Transaction Headlines and Highlights
4 Introduction Establish API, Sale of Minority Stake / Convertible Notes Transaction Headlines – Separate operating and royalty business segments – Significant magnitude of proceeds ($200M - $300M) – Investors: Ares Management, New Leaf Venture Partners – Proceeds to reduce Angiotech debt Transactio
Slide 7: Ares Management and New Leaf Venture Partners
5 Introduction Ares Management and New Leaf Venture Partners Ares Management – Manages $25 billion of committed capital in private equity, capital markets and private debt – Proven track record of deploying flexible capital in both majority and shared-control situations – Targets under-capitalized m
Slide 8: Evaluation of Strategic and Financial Alternatives
6 Introduction Evaluation of Strategic and Financial Alternatives Situation Review – Royalty revenue pressures –TAXUS / BSC – Limited ability to reduce debt as planned after acquisition of AMI – Operating cash flow negative during last several quarters – Magnitude, timing for new product growth – Qu
Slide 9: Our Business: Components of Value
7 Our Business Components of Value TAXUS ® DES and New Proprietary Pipeline, Research Medical Products Other Potential Products Portfolio, IP Portfolio Royalties Acquired per AMI 5-FU Platform Focused 5+ earlier stage manufacturing programs ~$110M in 2007 assets / vertical 5-FU CVC Significant numbe
Slide 10: Accessing Capital Through Components of Value
Strategic, Financial Alternatives Angiotech Pipctine, Research Portfolio, ‘© Portfolio New Proprietary Medical P. od ledical P. oducts Products F Acquired per AMI 8 Focused manufacturing assets / vertical “touch points” a 5-FU Platform a 5+ earlier stage grams Indreds of issued, nding patents 45M R
Slide 11: Benefits for All Key Capital Structure Constituents
9 Transaction Highlights Benefits for All Key Capital Structure Constituents Shareholders – Sell substantive API “equity” stake to capture significant capital proceeds • Greater magnitude, less dilution than would have been available with more conventional alternatives – Mitigate “TAXUS risk” • Lowe
Slide 12: Aligning Capital Structure and Business Strategies
10 Transaction Details Aligning Capital Structure and Business Strategies $165M - $265M debt reduction 52% to 68% Stake ANPI Additional financial, strategic alternatives – – Royalty business IPO / monetization of remaining API stake Potential future IPO Equity oriented capital structure API $200M -
Slide 13: Preliminary Pro Forma Financial Impact Illustration
11 Preliminary Pro Forma Financial Impact Illustration Angiotech Consolidated and Reporting Segments Royalty API $US in Millions 2007A 2007A PF $US in Millions Segment Segment Royalty Revenue $117 $117 Total Revenue $111 $177 Product Revenue $171 $171 Cost of Sales $0 $95 Royalty Expense $19 $0 Tota
Slide 14: Additional Transaction Details
12 Additional Transaction Details Selected Key Items Tender offer details – $165M initially available • $86M minimum for Senior FRNs Angiotech remaining debt – API Guarantee Conversion of convertible notes – Any time after September 2009 – Upon a “Qualified Transaction”: IPO of API at certain value
Slide 15: Conclusions
13 Conclusions Delivering Value, Risk Reduction, Strategy Raises substantial proceeds, reduce cash pay debt, improve coverage ratios Retains majority stake for ANPI shareholders (68% to 52%) Mitigate risks of uncertainty in the DES market Unlock and capture value embedded in non-TAXUS assets Flexibl
Angiotech Pharmaceuticals — Merger or Acquisition (July 2008) on 6ix